Current portfolio

XyloCor Therapeutics

US biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease

  • Sektor
    Healthcare
  • Land
    United States
  • Fond
    LSP 6
  • Entry
    2018
  • Web
Logo

Prenumerera

Prenumerera på EQT:s press releaser, regulatoriska press releaser och updates.

Typ av nyheter
Preferred language
EQT logo
En syftesdriven global investeringsorganisation
© EQT AB 2022. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180